Correction: Combination of betulinic acid and EGFR‑TKIs exerts synergistic anti‑tumor effects against wild‑type EGFR NSCLC by inducing autophagy‑related cell death via EGFR signaling

Correction: Combination of betulinic acid and EGFR‑TKIs exerts synergistic anti‑tumor effects against wild‑type EGFR NSCLC by inducing autophagy‑related cell death via EGFR signaling

Saved in:

Bibliographic Details
Main Authors:	Han Wang, Xiaohui Du, Wenwen Liu, Congcong Zhang, Ying Li, Jingwen Hou, Yi Yu, Guiru Li, Qi Wang
Format:	Article
Language:	English
Published:	BMC 2025-04-01
Series:	Respiratory Research
Online Access:	https://doi.org/10.1186/s12931-025-03223-8
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway
by: Han Wang, et al.
Published: (2024-05-01)

The Effects of Silibinin Combined With EGFR‐TKIs in the Treatment of NSCLC
by: Xiaocen Wang
Published: (2025-02-01)

Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs
by: Linwu Kuang, et al.
Published: (2025-03-01)

Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
by: Jin Tian, et al.
Published: (2024-12-01)

High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy
by: Shugui Wu, et al.
Published: (2025-05-01)

Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC
by: Yingqi Xu, et al.
Published: (2025-12-01)

The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis.
by: Han Yan, et al.
Published: (2015-01-01)

Risk factors for radiation pneumonitis in NSCLC patients treated with third-generation EGFR TKIs and chest radiotherapy
by: Nan Zhao, et al.
Published: (2025-05-01)

Sequencing the anti-EGFR-TKIs; route to the longest survival
by: H.G. Güzel, et al.
Published: (2024-12-01)

Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
by: Martina Ruglioni, et al.
Published: (2025-02-01)

Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs
by: Jietao Ma, et al.
Published: (2024-10-01)

GLUT1 sensitizes tumor cells to EGFR-TKIs by binding with activated EGFR and regulating its downstream signaling pathways
by: Zhangrong Xie, et al.
Published: (2025-05-01)

Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs
by: Jun Li, et al.
Published: (2024-12-01)

Application of EGFR-TKIs in brain tumors, a breakthrough in future?
by: Shiying Feng, et al.
Published: (2025-04-01)

Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC
by: Y. Uehara, et al.
Published: (2024-09-01)

Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer
by: Kibum Kim, et al.
Published: (2025-01-01)

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
by: Ning Lou, et al.
Published: (2024-12-01)

EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
by: Martin Sattler, et al.
Published: (2008-01-01)

Editorial: EGFR-TKIs for lung cancer treatment: development, application, and side effects
by: Qinglin Shen, et al.
Published: (2025-05-01)

Letter to the Editor: EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer
by: Hinpetch Daungsupawong PhD, et al.
Published: (2024-10-01)

Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLC
by: Lianxi Song, et al.
Published: (2025-09-01)

Combined EGFR and VEGFR versus single EGFR signaling pathways inhibition therapy for NSCLC: a systematic review and meta-analysis.
by: Xinji Zhang, et al.
Published: (2012-01-01)

Navigating the Evolving Treatment Paradigm for _EGFR_-Mutant NSCLC
by: Sebastian Kraus
Published: (2024-10-01)

Effects of EGFR-TKIs combined with intracranial radiotherapy in EGFR-mutant non-small cell lung cancer patients with brain metastases: a retrospective multi-institutional analysis
by: Mingfeng He, et al.
Published: (2025-01-01)

Central nervous system metastases of lung adenocarcinoma harboring EGFR-activating mutations: survival results from a multidisciplinary approach, including EGFR-TKIs
by: Guilherme Harada, et al.
Published: (2020-01-01)

EGFR‐TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer
by: Yuanzhou Zhang, et al.
Published: (2025-08-01)

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
by: Brian J. Thomas, et al.
Published: (2024-11-01)

High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study
by: Yin Pan, et al.
Published: (2025-11-01)

Aumolertinib plus bevacizumab for untreated advanced NSCLC with EGFR sensitive mutation
by: Lingping Kong, et al.
Published: (2025-06-01)

Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failure
by: Zong-Han Yao, et al.
Published: (2025-08-01)

Intracellular cholesterol: new functions and therapeutic approaches in NSCLC EGFR-TKI resistance
by: Linjuan Wang, et al.
Published: (2025-07-01)

Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboring EGFR 21 L858R mutation
by: Yan’e Liu, et al.
Published: (2025-06-01)

Machine learning approaches for EGFR mutation status prediction in NSCLC: an updated systematic review
by: Liu Haixian, et al.
Published: (2025-07-01)

Critical Review of *EGFR*-Mutated NSCLC What We Do and Do Not Know
by: Alexander Meisel, et al.
Published: (2020-03-01)

Baseline and changes in inflammatory parameters for patients with EGFR‐mutated NSCLC treated with afatinib
by: Zi‐Ting Chang, et al.
Published: (2025-07-01)

Simultaneous Occurrence of HER2 Mutations in EGFR Mutant NSCLC: Case Reports
by: Blerina Resuli, MD, et al.
Published: (2024-12-01)

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients
by: Xiaodong Chai, et al.
Published: (2025-08-01)

Research Status and Progress of Third-generation EGFR-TKIs  in Elderly Patients with Non-small Cell Lung Cancer
by: Xue CHEN, et al.
Published: (2025-05-01)

MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis
by: Defeng Hu, et al.
Published: (2025-04-01)

Evaluation Value of Blood Biomarker Tests for Efficacy of EGFR-TKI in Advanced NSCLC Treatment
by: Rui FAN, et al.
Published: (2025-05-01)